Market news

On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does […]

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and disappointments. Read more on ASND stock here.

Ascendis Pharma (ASND) share selloff on Tuesday after the termination of its collaboration agreement

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program). Purchases under the planned Share Repurchase Program may be made from time to time, in such amounts as management deems appropriate, through a variety of methods, which may include open market purchases, privately negotiated transactions, b

Ascendis Pharma A/S (NASDAQ:ASND) on Wednesday announced Week 52 data from the open-label sentinel cohort of its reACHin trial. The data showed that once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants with achondroplasia aged 0 to under 2 years. Read Also: Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes Growth And Cranio-Cervical Health Treatment with TransCon CN

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52 – Treatment with TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period COPENHAGEN, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Phar

Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, G

Mads Bodenhoff, Senior Vice President and Principal Accounting Officer, on September 08, 2026, sold

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondrop

Ascendis Pharma (NasdaqGS:ASND) drew fresh investor attention after Canada’s Drug Agency recommended conditional public reimbursement for Yorvipath, its parathyroid hormone replacement therapy for eligible adults with chronic hypoparathyroidism. Ascendis Pharma’s recent news flow, including the Canadian reimbursement recommendation for Yorvipath and the late August global settlement with BioMarin over Yuviwel, has arrived alongside strong price momentum, with a 90 day share price return of...

Ascendis Pharma (NasdaqGS:ASND) reached a global settlement and licensing agreement with BioMarin Pharmaceutical that resolves worldwide patent disputes related to Yuviwel. The deal grants Ascendis Pharma a license to continue commercializing Yuviwel and related products across global markets. Ascendis Pharma also received a positive reimbursement recommendation in Canada for Yorvipath for adults with chronic hypoparathyroidism. These legal and reimbursement outcomes affect Ascendis Pharma's...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma’s Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injection approved by the FDA to increase linear height growth in children aged 2 years and older with achondroplasia who have open growth plates. In March, the FDA approved Yuviwel, the first and only once-w

COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies. Under the terms, BioMarin has agreed to gr

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Kor

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of

On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come. Total product revenue roughly doubled from a year earlier to €315 million, and for the first time all three of the company’s approved TransCon therapies, SKYTROFA, YORVIPATH and YUVIWEL, were contributing meaningful sales in the same […]

Ascendis Pharma stock has delivered a 5.8% gain year to date, yet current valuation checks and market pricing point to a company that is not clearly cheap at today’s levels. With recent positive clinical updates and index inclusion in the background, the key issue for investors is how much of that optimism is already embedded in the share price. Year to date, Ascendis Pharma is up 5.8%, which suggests recent news and progress are being recognized but not in a runaway rally. Progress across...